Oxyntomodulin for preventing or treating excess weight

• US 7,666,835 B2
• Filed: 09/09/2002
• Issued: 02/23/2010
• Est. Priority Date: 09/07/2001
• Status: Expired due to Fees

• Current Assignee: Imperial Innovations Limited (Imperial College London)
• Original Assignee: Imperial Innovations Limited (Imperial College London)
• Inventors: Ghatei, Mohammad Ali, Small, Caroline Jane, Bloom, Stephen Robert, Dakin, Catherine Louise
• Primary Examiner(s): Kosar; Andrew D
• Application Number:
  US10/488,341
• Publication Number:
  US 20050070469A1
• Time in Patent Office: 2,724 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/543 Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.

Claims

1. A method for the treatment or management of excess weight in a mammal in need thereof, comprising peripherally administering to said mammal oxyntomodulin comprising the amino acid sequence of SEQ ID NO:

1, 2 or 3, or a pharmaceutically acceptable salt thereof, in an amount effective to treat or manage the excess weight in said mammal.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein said excess weight is a symptom of obesity.

4. The method of claim 1, wherein cosmetic weight loss is achieved.

5. The method of claim 1, wherein said oxyntomodulin is administered to said mammal by parenteral, intraperitoneal, or subcutaneous administration.

12. The method of claim 1 or 6, wherein said oxyntomodulin is administered to said mammal by inhalation or by buccal, sublingual or nasal administration.

13. The method of claim 1 or 6, wherein said oxyntomodulin is administered to said mammal in the presence of a metal.

14. The method of claim 13, wherein the metal is selected from the group consisting of calcium, magnesium, manganese and zinc.

15. The method of claim 1 or 6, wherein said oxyntomodulin comprises the amino acid sequence of SEQ ID NO:

1.

16. The method of claim 1 or 6, wherein said oxyntomodulin comprises the amino acid sequence of SEQ ID NO:

2.

17. The method of claim 1 or 6, wherein said oxyntomodulin comprises the amino acid sequence of SEQ ID NO:

3.

18. The method of claim 1 or 6, wherein said oxyntomodulin is human oxyntomodulin.

6. A method for the treatment or management of obesity in a mammal in need thereof, comprising administering to said mammal oxyntomodulin comprising the amino acid sequence of SEQ ID NO:

1, 2 or 3, or a pharmaceutically acceptable salt thereof, in an amount effective to treat or manage obesity in said mammal.

7. The method of claim 6, wherein said mammal is a human.

8. The method of claim 6, wherein said excess weight is a symptom of obesity.

9. The method of claim 6, wherein cosmetic weight loss is achieved.

10. The method of claim 6, wherein said oxyntomodulin is administered to said mammal by parenteral, intraperitoneal, or subcutaneous administration.

11. The method of claim 6, wherein the oxyntomodulin is administered by peripheral administration.